3.05
-0.1(-3.17%)
Currency In USD
| Previous Close | 3.15 |
| Open | 3.09 |
| Day High | 3.16 |
| Day Low | 2.99 |
| 52-Week High | 47.6 |
| 52-Week Low | 1.65 |
| Volume | 54,495 |
| Average Volume | 698,329 |
| Market Cap | 5.34M |
| PE | -0.11 |
| EPS | -29.03 |
| Moving Average 50 Days | 2.48 |
| Moving Average 200 Days | 7.1 |
| Change | -0.1 |
If you invested $1000 in Indaptus Therapeutics, Inc. (INDP) 10 years ago, it would be worth $0.3 as of January 14, 2026 at a share price of $3.05. Whereas If you bought $1000 worth of Indaptus Therapeutics, Inc. (INDP) shares 5 years ago, it would be worth $6.27 as of January 14, 2026 at a share price of $3.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
GlobeNewswire Inc.
Dec 29, 2025 12:00 PM GMT
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces i
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced t
Indaptus Therapeutics Provides Clinical Update
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSW